Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
AUROBINDO PHARMA | ABBOTT INDIA | AUROBINDO PHARMA/ ABBOTT INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 17.8 | 47.8 | 37.3% | View Chart |
P/BV | x | 3.9 | 15.6 | 24.7% | View Chart |
Dividend Yield | % | 0.3 | 0.4 | 61.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
ABBOTT INDIA Mar-19 |
AUROBINDO PHARMA/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 8,834 | 9.4% | |
Low | Rs | 527 | 5,458 | 9.7% | |
Sales per share (Unadj.) | Rs | 333.9 | 1,731.1 | 19.3% | |
Earnings per share (Unadj.) | Rs | 40.4 | 211.9 | 19.0% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 219.9 | 23.5% | |
Dividends per share (Unadj.) | Rs | 2.50 | 65.00 | 3.8% | |
Dividend yield (eoy) | % | 0.4 | 0.9 | 40.5% | |
Book value per share (Unadj.) | Rs | 237.1 | 945.2 | 25.1% | |
Shares outstanding (eoy) | m | 585.91 | 21.25 | 2,757.2% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 4.1 | 49.2% | |
Avg P/E ratio | x | 16.8 | 33.7 | 49.9% | |
P/CF ratio (eoy) | x | 13.1 | 32.5 | 40.3% | |
Price / Book Value ratio | x | 2.9 | 7.6 | 37.9% | |
Dividend payout | % | 6.2 | 30.7 | 20.2% | |
Avg Mkt Cap | Rs m | 397,569 | 151,848 | 261.8% | |
No. of employees | `000 | 17.9 | 3.5 | 512.3% | |
Total wages/salary | Rs m | 25,849 | 4,356 | 593.4% | |
Avg. sales/employee | Rs Th | 10,956.9 | 10,555.5 | 103.8% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,249.9 | 115.8% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 1,292.2 | 102.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 36,786 | 531.8% | |
Other income | Rs m | 1,553 | 1,133 | 137.1% | |
Total revenues | Rs m | 197,189 | 37,919 | 520.0% | |
Gross profit | Rs m | 39,519 | 6,047 | 653.5% | |
Depreciation | Rs m | 6,680 | 169 | 3,947.7% | |
Interest | Rs m | 2,626 | 23 | 11,671.1% | |
Profit before tax | Rs m | 31,767 | 6,989 | 454.6% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | 2,485 | 292.5% | |
Profit after tax | Rs m | 23,645 | 4,503 | 525.1% | |
Gross profit margin | % | 20.2 | 16.4 | 122.9% | |
Effective tax rate | % | 22.9 | 35.6 | 64.3% | |
Net profit margin | % | 12.1 | 12.2 | 98.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 27,610 | 556.5% | |
Current liabilities | Rs m | 120,429 | 8,569 | 1,405.4% | |
Net working cap to sales | % | 17.0 | 51.8 | 32.8% | |
Current ratio | x | 1.3 | 3.2 | 39.6% | |
Inventory Days | Days | 135 | 60 | 224.5% | |
Debtors Days | Days | 64 | 27 | 232.5% | |
Net fixed assets | Rs m | 103,909 | 1,057 | 9,831.6% | |
Share capital | Rs m | 586 | 213 | 275.7% | |
"Free" reserves | Rs m | 138,322 | 19,873 | 696.0% | |
Net worth | Rs m | 138,908 | 20,086 | 691.6% | |
Long term debt | Rs m | 1,800 | 0 | - | |
Total assets | Rs m | 264,544 | 29,409 | 899.5% | |
Interest coverage | x | 13.1 | 311.6 | 4.2% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 1.3 | 59.1% | |
Return on assets | % | 9.9 | 15.4 | 64.5% | |
Return on equity | % | 17.0 | 22.4 | 75.9% | |
Return on capital | % | 23.8 | 34.9 | 68.3% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 369 | 26,375.9% | |
Fx outflow | Rs m | 40,589 | 4,918 | 825.2% | |
Net fx | Rs m | 56,727 | -4,549 | -1,246.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 4,991 | 325.0% | |
From Investments | Rs m | -28,768 | -2,570 | 1,119.4% | |
From Financial Activity | Rs m | 19,191 | -1,428 | -1,343.9% | |
Net Cashflow | Rs m | 6,656 | 993 | 670.1% |
Indian Promoters | % | 54.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 7.9 | 100.6% | |
FIIs | % | 27.7 | 0.1 | 27,700.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 17.1 | 59.6% | |
Shareholders | 69,601 | 18,270 | 381.0% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: DR. DATSONS LABS DISHMAN PHARMA J.B.CHEMICALS JUBILANT LIFE SCIENCES DIVIS LABORATORIES
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More